HUE032153T2 - Anti-BAFF anti-IL-17 bispecific antibodies - Google Patents

Anti-BAFF anti-IL-17 bispecific antibodies Download PDF

Info

Publication number
HUE032153T2
HUE032153T2 HUE13726321A HUE13726321A HUE032153T2 HU E032153 T2 HUE032153 T2 HU E032153T2 HU E13726321 A HUE13726321 A HU E13726321A HU E13726321 A HUE13726321 A HU E13726321A HU E032153 T2 HUE032153 T2 HU E032153T2
Authority
HU
Hungary
Prior art keywords
bispecific antibody
seq
baff
human
antibody
Prior art date
Application number
HUE13726321A
Other languages
English (en)
Hungarian (hu)
Inventor
Barrett Allan
Robert Jan Benschop
Jirong Lu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE032153T2 publication Critical patent/HUE032153T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE13726321A 2012-04-20 2013-04-16 Anti-BAFF anti-IL-17 bispecific antibodies HUE032153T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
US201361768747P 2013-02-25 2013-02-25

Publications (1)

Publication Number Publication Date
HUE032153T2 true HUE032153T2 (en) 2017-09-28

Family

ID=48539373

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13726321A HUE032153T2 (en) 2012-04-20 2013-04-16 Anti-BAFF anti-IL-17 bispecific antibodies

Country Status (39)

Country Link
US (2) US9359448B2 (en:Method)
EP (2) EP2838920B1 (en:Method)
JP (1) JP6216772B2 (en:Method)
KR (1) KR101673735B1 (en:Method)
CN (1) CN104220455B (en:Method)
AP (1) AP2014008002A0 (en:Method)
AR (1) AR090626A1 (en:Method)
AU (1) AU2013249546B2 (en:Method)
BR (1) BR112014025649A2 (en:Method)
CA (1) CA2869148C (en:Method)
CL (1) CL2014002616A1 (en:Method)
CO (1) CO7160039A2 (en:Method)
CR (1) CR20140466A (en:Method)
CY (1) CY1118824T1 (en:Method)
DK (1) DK2838920T3 (en:Method)
DO (1) DOP2014000234A (en:Method)
EA (1) EA029185B1 (en:Method)
EC (1) ECSP14023405A (en:Method)
ES (2) ES2789474T3 (en:Method)
GT (1) GT201400217A (en:Method)
HR (1) HRP20170468T1 (en:Method)
HU (1) HUE032153T2 (en:Method)
IL (1) IL234965B (en:Method)
IN (1) IN2014MN01876A (en:Method)
LT (1) LT2838920T (en:Method)
ME (1) ME02596B (en:Method)
MX (1) MX367460B (en:Method)
MY (1) MY173282A (en:Method)
NZ (1) NZ630865A (en:Method)
PE (1) PE20142147A1 (en:Method)
PH (1) PH12014502333B1 (en:Method)
PL (1) PL2838920T3 (en:Method)
PT (1) PT2838920T (en:Method)
RS (1) RS55729B1 (en:Method)
SG (1) SG11201406726PA (en:Method)
SI (1) SI2838920T1 (en:Method)
TW (1) TWI585103B (en:Method)
WO (1) WO2013158577A1 (en:Method)
ZA (1) ZA201407272B (en:Method)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6120767B2 (ja) 2010-05-20 2017-04-26 アブリンクス ナームローゼ・フェノーツハップＡｂｌｙｎｘ ＮＶ Ｈｅｒ３に関連する生物学的材料
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EP3071024B1 (en) * 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
MX367661B (es) 2014-01-31 2019-08-30 Boehringer Ingelheim Int Anticuerpos anti-baff novedosos.
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
PE20180774A1 (es) 2015-07-23 2018-05-07 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
WO2019136311A2 (en) * 2018-01-05 2019-07-11 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
WO2022258045A1 (zh) * 2021-06-11 2022-12-15 山东先声生物制药有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
KR20250127162A (ko) * 2022-12-28 2025-08-26 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 항-baff 항체를 포함하는 이중특이적 결합 단백질 및 이의 용도
WO2024197157A1 (en) 2023-03-21 2024-09-26 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025222167A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
SG2014010029A (en) * 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
KR101158959B1 (ko) * 2005-12-13 2012-07-09 일라이 릴리 앤드 캄파니 항-ｉｌ-17 항체
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Also Published As

Publication number Publication date
US20160251430A1 (en) 2016-09-01
EP2838920B1 (en) 2017-02-01
ES2621917T3 (es) 2017-07-05
CA2869148A1 (en) 2013-10-24
CL2014002616A1 (es) 2015-01-30
ECSP14023405A (es) 2015-09-30
HK1201862A1 (en) 2015-09-11
US9359448B2 (en) 2016-06-07
SG11201406726PA (en) 2014-11-27
JP2015514423A (ja) 2015-05-21
IL234965B (en) 2018-04-30
ZA201407272B (en) 2016-11-30
EP2838920A1 (en) 2015-02-25
CR20140466A (es) 2014-11-13
TW201402607A (zh) 2014-01-16
HRP20170468T1 (hr) 2017-06-02
PT2838920T (pt) 2017-05-03
AP2014008002A0 (en) 2014-10-31
TWI585103B (zh) 2017-06-01
AU2013249546B2 (en) 2017-10-26
IN2014MN01876A (en:Method) 2015-07-03
CO7160039A2 (es) 2015-01-15
MX2014012692A (es) 2015-01-22
WO2013158577A1 (en) 2013-10-24
CA2869148C (en) 2017-06-20
NZ630865A (en) 2016-02-26
EP3192809A1 (en) 2017-07-19
RS55729B1 (sr) 2017-07-31
SI2838920T1 (sl) 2017-03-31
CN104220455B (zh) 2017-04-26
CY1118824T1 (el) 2018-01-10
BR112014025649A2 (pt) 2017-07-04
US20130280256A1 (en) 2013-10-24
GT201400217A (es) 2015-06-02
PH12014502333A1 (en) 2014-12-22
JP6216772B2 (ja) 2017-10-18
AU2013249546A1 (en) 2014-09-25
ES2789474T3 (es) 2020-10-26
LT2838920T (lt) 2017-05-25
CN104220455A (zh) 2014-12-17
DOP2014000234A (es) 2014-11-30
KR101673735B1 (ko) 2016-11-07
EP3192809B1 (en) 2020-04-15
PL2838920T3 (pl) 2017-07-31
AR090626A1 (es) 2014-11-26
PH12014502333B1 (en) 2014-12-22
EA029185B1 (ru) 2018-02-28
EA201491622A1 (ru) 2015-01-30
PE20142147A1 (es) 2014-12-13
DK2838920T3 (en) 2017-04-18
US9708402B2 (en) 2017-07-18
ME02596B (me) 2017-06-20
KR20140135830A (ko) 2014-11-26
MY173282A (en) 2020-01-10
MX367460B (es) 2019-08-22

Similar Documents

Publication Publication Date Title
DK2838920T3 (en) BISPECIFIC ANTI-BAFF-ANTI-IL-17 ANTIBODIES
RU2732032C2 (ru) Антитела с двойной специфичностью
CN112424223B (zh) 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
US20200277366A1 (en) MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
JP7163275B2 (ja) 抗－ｉｌ－２２ｒ抗体
CN107207623A (zh) Fc融合高亲和力IgE受体α链
KR20170016501A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
KR102598319B1 (ko) 항-il-25 항체 및 그의 용도
JP7688150B2 (ja) 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
HK1201862B (en) Anti-baff-anti-il-17 bispecific antibodies
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
WO2025222170A1 (en) Methods of treatment
WO2025222167A1 (en) Methods of treatment
WO2025222168A1 (en) Methods of treatment
EP4405391A1 (en) Anti-il-1-beta antibodies
JP2018515437A (ja) 抗ｃｄ２０／抗ｂａｆｆ二重特異性抗体